



OFF-X 2024年の機能強化点を含めた 基本編ウェブセミナー

製薬企業・保健当局における研究と意思決定のための
実用的な毒性・安全性情報プラットフォーム

Clarivate Life Sciences & Healthcare Webinar | April 24th, 2025

本日の内容

1. 毒性・安全性情報プラットフォーム OFF-X概要
2. 新インターフェース TOP画面
3. 知識分野別 活用事例
 - ターゲット分子
 - 医薬品
 - 有害事象
4. サポートのご案内

※機能強化があった箇所に言及したスライドに**New**をつけています

OFF-X

前臨床毒性から臨床有害事象まで全世界の医薬品安全性情報を収集し、製薬企業・保健当局における様々な研究や意思決定を支える実用的な毒性・安全性情報プラットフォーム

OFF-X

The translational safety intelligence portal

Data※

-304万+ 毒性・安全性アラート

-15,600+ ターゲットと遺伝子

-42,600+ 医薬品と生物製剤
(前臨床から市販後まで)

-14,500+ 有害事象エンドポイント

※As of April 2025

Source coverage

-査読付き文献

-会議/会議録

-臨床試験登録

-規制関連文書

-企業広報

-FAERSおよびJADER

博士号取得および医学博士レベルの研究専門家チームによる100%のマニュアルキュレーション

- 医薬品の研究開発から市販後までの全段階における安全性情報の包括的な「ワンストップ」リソース

- 統合された幅広いデータソース

- 専門家のキュレーションによる前臨床－臨床安全性情報と高度な分析

- すべての薬剤モダリティをカバー

- 毎日更新


医薬品とターゲットの安全性情報へ、より効率的にアクセスすることで、調査時間を節約

Sources of information

PhDおよびMDレベルの研究専門家チームによる100%マニュアルキュレーション：

- **生物医学文献**：PubMed（Medline + PubMed Central）および優先度の高い非インデックスジャーナル
- **会議および科学会議**：年間550の科学イベントをカバー
- **企業発表**：>1,800以上の機関
- **主要臨床試験レジストリ**
- **規制当局**：FDA、EMA、PMDA、MHRAの承認パッケージの手動キュレーション + FDAのSummary Basis of Approval (SBA)文書のテキストマイニング
- **規制当局**：（FDA、EMA、UK MHRA、PMDA、カナダ保健省、オーストラリア TGA、スペイン AEMPS、フランス ANSM、ブラジル ANVISA、スイスメディック、ニュージーランド MARC、シンガポール HSA、マレーシア NPRA）からの安全性情報およびラベル変更
- **RWD**：FAERS, JADER

Editorial workflow and analysis



セーフティアラート：あらゆる情報源をカバーしタイムリーな安全性情報を提供

February 16, 2017 • Journal

Confirmed/Reported

On-Target

Causality

Adverse Event **Anaemia**

Alert Phase **Clinical/Postmarketing**

Exhaustive review of scientific literature to identify the most likely functional and pathological outcomes associated with interactions of 70 molecular targets with established links to adverse effects. In humans, androgen receptor antagonists caused osteoporosis, sexual dysfunction, impaired memory and attention, depression, hot flushes, anemia, increased triglycerides, insulin resistance, increased body weight, bone metastasis, bone pain and death (due to heart attack).

Type

Class Alert

On/off-target

On-Target

Source information [See all alerts](#)

Reference date

February 16, 2017

Title

Potential functional and pathological side effects related to off-target pharmacological activity

Citation

J Pharmacol Toxicol Methods. 2017 Feb 16. pii: S1056-8719(16)30147-2

PubMed

[28216264](#)

● ON/OFF-ターゲット：有害事象がターゲットの直接修飾によるものか非直接的な機序によるものかを区別

● アラートタイプ：ターゲットと有害事象の関連性が、薬理学的クラス全体に認められるものか、特定の薬物に関連するものかを区別

● アラートフェーズ：有害事象が報告された開発段階（ターゲットの発見～前臨床、臨床試験、上市医薬品）

● アナリスト（生物学者、薬事学者、メディカルケミスト、毒性学者、MD）によるアラートサマリ

● エビデンスレベル：ターゲット・薬物と有害事象の関連性に関するエビデンスの度合い

OFF-X 知識分野



専門家によるOFF-Xのセーフティーアラートは、**3つの知識分野**に統合、毎日更新されます。幅広く、かつ深いコンテンツは**一つの統合された環境**で提供され、各分野間の**クロスリンク**が、重要なインサイトの発見と意思決定をサポートします。

Target: Androgen receptor / Antagonists

Snapshot | Safety alerts | Target safety profile | Comparative views | Biological context

Class Nuclear Hormone Receptors Allosteric (8) AR DHTR Dihydrotestosterone receptor Kennedy disease NR3C4 Nuclear receptor subfamily 3 group C member 4 SBMA ...	Family Steroid hormone receptors Subfamily 3-Ketosteroid receptors	OFF-X target ID 1580 Gene (1) AR	UniProt ID (1) P10275 Cortellis Drug Discovery Intelligence (1) G367 MetaCore (2) -1467284547, 4423
---	--	---	---

Drug: mirikizumab

Snapshot | Safety alerts | Drug safety profile | Comparative views

Drug type Y Biologic Product category/modality Humanized Monoclonal Antibodies	Highest phase Launched 2023 Drug names (5) mirikizumab-mrkz Omvoh LY-3074828 LY3074828 Z7HVY03PHP	OFF-X drug ID 142617 Organizations (1) Eli Lilly and Company	Cortellis Drug Discovery Intelligence (1) 826704 Cortellis Competitive Intelligence (1) 87792 DrugCentral (1) mirikizumab ChEMBL (1) ChEMBL3990014
---	--	---	---

Adverse event: Anaemia

Targets | Drugs and biologics

Master view
Showing 1,414 target-actions


Filter Columns

Target * Action	OFF-X Target/Class Score	Classifier tags	Number of alerts	Alert type	Alert phase
ACE * Inhibitors	Very high	On-Target Causality	35	13	11 4 24 13 3 2
Androgen receptor * Antagonists	Very high	On-Target Causality Severity	85	12	4 0 81 12 0 0
BCMA-targeted CAR T-cells * (no specific action)	Very high	On-Target Causality Severity	139	26	1 0 138 26 0 0
BCR/ABL * Inhibitors	Very high	Causality Severity Pharmacogenomics	209	13	4 6 205 13 0 0

What is an OFF-X safety alert?

薬物または標的分子への作用と有害事象との間に報告された
関連性とその情報源

これら三つはOFF-Xの重要な構成要素であり、ユーザーによる評価と安全性の洞察を容易にするため、編集チームによって手作業で情報のキュレーションを行い、インデックス化された追加データ（40以上のフィールド）と合わせて提供されます。



June 1, 2024 • Congress Alert

Title

Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study

Citation

ASCO Annual Meeting 2024 - J Clin Oncol 42, 2024 (suppl 16; abstr 2591)

Showing 1 safety alert

Target-centric

Drug-centric

Collapse all

Phase I/II study analyzing the safety and efficacy of LBL-015 (PD-1 inhibitor; 0.3-20 mg/kg IV q2w) in 25 patients with advanced malignant tumors. The most common grade ≥3 treatment-emergent adverse events (TEAEs) included anaemia (any grade 16 patients [64%], grade ≥3 4 patients [16%]) and hypoalbuminemia (5 [20%], 1 [4%]). Other most common TEAEs were increased AST (8 [32%]), proteinuria, pyrexia, increased GGT and bleeding gingival (7 [28%] each). Other safety issues are listed.

Alert date

June 10, 2024

Clinical trial ID (1)

NCT05107011

Clinical Trial record

1 alert

Cortellis Clinical Trials Intelligence

Target • Action	Adverse Event • System Organ Class	Classifier Tags	Association based on reference	On/off-target	Alert type	Alert phase	Drugs and combinations	Tools
PD-1 • Inhibitors	Alanine aminotransferase increased • Investigations	On-Target	Confirmed/Reported	On-Target	Drug Alert	Phase I/II	LBL-015	
PD-1 • Inhibitors	Anaemia • Blood and lymphatic system disorders	On-Target Severity	Confirmed/Reported	On-Target	Drug Alert	Phase I/II	LBL-015	
PD-1 • Inhibitors	Aspartate aminotransferase increased • Investigations	On-Target	Confirmed/Reported	On-Target	Drug Alert	Phase I/II	LBL-015	

Clarivate™

8
© 2025 Clarivate

OFF-X Drug Score, Target/ Class Score, Drug Combination Score

安全性に関するインサイトを導きだすための独自指標

- ※ 一定の「ルール」に基づく分類であり統計的な手法ではありません
- ※ これらのScoreは以下を示すものではありません
 - ・ 医薬品・医薬品クラスと有害事象の因果関係
 - ・ 有害事象の発生率
 - ・ 有害事象の重篤度

New

OFF-X Drug Score

特定の「**医薬品－有害事象**」の組み合わせについて蓄積されたセーフティアラートに基づき、当該「**医薬品－有害事象**」の関連性を示すエビデンスの強さを計算して分類


例：Androgen receptor Antagonistsの有害事象プロファイル
をDrug Scoreのヒートマップで比較



OFF-X Target / Class Score

特定の「**(同じターゲットに作用する) 医薬品クラス－有害事象**」の組み合わせについて蓄積されたセーフティアラートに基づき、当該「**医薬品クラス－有害事象**」の関連性を示すエビデンスの強さを計算して分類


例：医薬品クラス（Androgen receptor Antagonists）の有害事象のプロファイルをTarget/Class Coreのエビデンスのヒートマップで把握



OFF-X Drug Combination Score

特定の「**コンビネーション－有害事象**」の組み合わせについて蓄積されたセーフティアラートに基づき、当該「**コンビネーション－有害事象**」の関連性を示すエビデンスの強さを計算して分類

例：Combination（alogliptin/metformin）の有害事象のプロファイルをDrug Combination Scoreのエビデンスを含めてMaster viewで把握





新インターフェース基本操作

New

新たなOFF-Xのプラットフォーム

		Biological Role & Preclinical Pharmacological Evidence			Clinical Pharmacological Evidence				
System Organ Class	OFF-X Target/Class Score	Target Expression	In vitro Data / Patient samples	Preclinical	↓ Phase I	Phase II	Phase III	Clinical Regulatory	Postmarketing
Investigations	High		Species 1 2 2	Species 4 118 14	214 17	148 5	57 2	37 1	20 2
Gastrointestinal disorders DME	High	DNA		Species 2 7 2	212 17	119 6	39 2	28 2	12 1
General disorders and administration site conditions DME	Medium			Species 4 9 7	66 14	60 4			
Metabolism and nutrition disorders	Medium			Species 3 10 3	66 15	39 5			
Blood and lymphatic system disorders DME	Medium	DNA		Species 3 6 2	48 13	28 4			
Skin and subcutaneous tissue disorders DME	Medium	DNA	Species 1 1 1	Species 1 3 2	39 9	30 5			
Nervous system disorders DME	Medium	DNA		Species 2 2 2	26 5	25 4			

What's new in OFF-X



Faster
OFF-X records load up to 80% faster



More intuitive
The OFF-X you know but with a new look and feel to improve your experience.



Customizable
Choose the content you want to see in the different tables and visualizations.

2024年7月、OFF-Xはユーザーからのフィードバックを受け、新たな技術スタックを用いて全く新しいプラットフォームにて提供開始されました。

Home page

OFF-Xに搭載されている分析ツールへ直接アクセス

OFF-X

Home

Analytics

Notification center

アラート機能の管理ページへアクセスし、設定の変更等が可能

クリックすることでHome pageへ戻ります

Welcome back, [User Name]

Targets

Drugs and biologics

Drug combinations

Adverse events

Type target or gene or UniProt ID and select

Targets, Drugs (Drugs & biologics, Drug combinations), Adverse Eventsの3軸で検索が可能。検索時にはいずれかを選択。

作成したアラートに関する直近の通知を表示

規制当局由来の新薬承認情報、添付文書改訂情報、臨床保留命令情報、試験・開発中止情報を表示

Your notifications

Latest alerts

Congress reports

直近で開催された学会情報を基に作成されたセーフティアラートへのアクセスや直近で開催予定の学会一覧を表示

androgen receptor_keep me posted

March 20, 2025 • Journal

Retrospective pharmacoepidemiologic study evaluating the drug-induced pulmonary fibrosis using data from Russian national pharmacovigilance database. The drugs induced pulmonary fibrosis included rituximab (5.5% patients), methotrexate (4.4%), etanercept (4.2%), leflunomide (4%) and adalimumab (3.7%). Other drugs are listed.

Citation
Biomedicines. 2024 Nov 21;12(12):2650
PubMed
39767557

See all alerts

androgen receptor_keep me posted

March 14, 2025 •

Retrospective study evaluating the effect of enzalutamide (150 mg daily) on fatigue in 153 patients with prostate cancer. Enzalutamide discontinuation was fatigue.

Citation
77th Annual Scientific Meeting of the Urological Society of Australia and New Zealand 2025 - BJ...

See all alerts

製品サイトやナレッジベース、機能強化のお知らせ通知等のサポートコンテンツへアクセス

Support

Analytics（分析ツールへの直接アクセス）

OFF-X

Home

Analytics

Notification center

Targets

Type target or gene or UniProt ID and select

活用用途を選択

Data in action to de-risk your R&D programs

All use cases

Target safety assessment

Toxicity exploration

Secondary pharmacology profiling

Preclinical to clinical translation

Structure-toxicity assessment

Mechanistic toxicity evaluation

Drug vs class assessment

Safety profile benchmark

Safety risk evaluation

Comparative table builder

Anticipate safety issues of new compounds and combinations, benchmark drugs and targets and assess the mechanisms behind adverse events.

Mounting evidence chart

Discover and compare drug-safety trends to anticipate emerging concerns

Pathway maps

Anticipate and understand safety issues of targets based on upstream or downstream genes in their signaling cascade

Real-world evidence analysis

Assess and validate potential pharmacovigilance signals to optimize risk management plans

Secondary pharmacology panels

Explore an integrated view of safety-related targets to keep your in vitro panels updated

Structure-toxicity explorer

Correlate chemical structures with safety liabilities.

Translational safety

Assess the correlation of safety insights of targets and drugs from discovery to clinical

Unexpected toxicity evaluation

Assess the mechanisms behind unpredicted adverse events

活用用途に応じた分析ツールを表示

Clarivate™

© 2025 Clarivate 13

アラート機能の設定と管理

②アラート名を編集し、通知を受け取る情報の範囲を設定後にApplyボタンをクリックすることで、当該レコードに対してアラートが設定されます。

Targetsレコード 例：PD-1

OFF-X Home Analytics Notification center Targets

Target PD-1 / Inhibitors

Comparative table builder

Keep me posted

Snapshot Safety alerts Target safety profile Comparative views Biological context

Drugレコード 例：Pegcetacoplan

OFF-X Home Analytics Notification center Drugs and biologics

Drug pegcetacoplan

Comparative table builder

Keep me posted

Snapshot Safety alerts Drug safety profile Comparative views

①DrugおよびTargetレコード上では、画面右に表示された「Keep me posted」をクリックすることでアラート機能の設定が可能です。

Set up your email notification

See customized content on your home page and receive email notifications.

Drug

pegcetacoplan

Notification name*
pegcetacoplan_keep me posted

Frequency
Weekly

Add description

What do you want to get notified about?

All new safety alerts New regulatory alerts only New adverse events only

Select adverse events Select SOC's Select SMQs

☐ Include safety alerts of drugs belonging to the same class *New*

☐ Include combination therapies of this drug

☐ Include retrospective content

Cancel Apply

アラート機能の設定と管理

OFF-X

HomeAnalyticsNotification center

type target or gene or UniProt ID and select

Notification center

Manage and edit your notifications

All notifications will be sent weekly to:

Your notifications

Active	Notification name	Knowledge area	Date created ↓	Description	Actions
☒	pegcetacoplan_keep me posted	Drugs & Biologics	Mar 21, 2025		 
☒	androgen receptor_keep me posted	Targets	Sep 11, 2024		 

Items per page: 5Page 1 of 1

Your weekly report

The weekly report lists all new safety alerts that have been added to OFF-X during the week.

☒ Receive the weekly report

Target-centricDrug-centric

③ Notification centerをクリックすることで、設定済みのアラートの管理画面を表示

④ アラートごとに通知のON/OFF管理が可能

⑤ アラートの削除や編集が可能

週に一度、期間中に新たな作成、通知された Safety Alertのリストを受信するか否か設定可能

アラート機能の設定と管理

Home画面上のYour notificationsに、設定した内容に基づく最新のアラート通知を表示

TargetsDrugs and biologicsDrug combinationsAdverse events

Type target or gene or UniProt ID and select

Your notificationsLatest alertsCongress reports

androgen receptor_keep me posted

March 20, 2025 • Journal

Retrospective pharmacoepidemiologic study evaluating the drug-induced pulmonary fibrosis using data from Russian national pharmacovigilance database. The drugs induced pulmonary fibrosis included rituximab (5.5% patients), methotrexate (4.4%), etanercept (4.2%), leflunomide (4%) and adalimumab (3.7%). Other drugs are listed.

Citation

Biomedicines. 2024 Nov 21;12(12):2650

PubMed

39767557

See all alerts

androgen receptor_keep me posted

March 14, 2025 • Congress Alert

Retrospective study evaluating the adverse events associated with androgen receptor pathway inhibitors (including abiraterone and enzalutamide) in 153 patients with metastatic prostate cancer and castration-resistant prostate cancer. The most common reason for enzalutamide discontinuation was fatigue.

Citation

77th Annual Scientific Meeting of the Urological Society of Australia and New Zealand 2025 - BJ...

See all alerts

androgen receptor_keep me posted

March 13, 2025 • Congress Alert

Phase III study of darolutamide (androgen receptor antagonist) in patients with metastatic hormone-sensitive prostate cancer. The most common treatment-emergent adverse events (TEAEs) included fatigue (223/652 patients [34%] with darolutamide vs 214/650 [33%] with placebo), rash (116 [18%] vs 88 [14%]) and hypertension (96 [15%] vs 60 [9%]). Other TEAEs are listed.

androgen receptor_keep me posted

March 13, 2025 • Journal

Real-world pharmacovigilance study evaluating the association between drugs and dementia risk using data from FAERS database. Study showed that rivastigmine (ROR: 46.3 [95% CI; 43.51-49.28]), nicergoline (43.34 [15.75-119.25]), aducanumab (30.19 [19.68-46.29]), amlodipine/atorvastatin (22.68 [11.67-44.09]) and dihydroergometrine (22.57 [9.25-55.06]) had higher risk of dementia. Other

レファレンスの一括出力

Adverse Eventsごとに作成されたセーフティアラートのレファレンスを一括で外部出力することが可能です。

Target
PD-1 / Inhibitors

Snapshot Safety alerts Target safety profile Comparative views

Adverse Events

> Blood and lymphatic system disorders DME 1726

On-Target Causality Severity Pharmacogenomics

> Cardiac disorders DME 1739

On-Target Causality Severity Pharmacogenomics

> Congenital, familial and genetic disorders DME 30

On-Target Causality Severity

> Ear and labyrinth disorders DME 62

On-Target Causality Severity

> Endocrine disorders 3364

On-Target Causality Severity

Adverse Events

> Blood and lymphatic system ... DME

> Cardiac disorders DME

> Congenital, familial and gene... DME

> Ear and labyrinth disorders DME

Auricular swelling

Autoimmune inner ear disease

Deafness neurosensory DME

Deafness

Ear discomfort

Showing 62 safety alerts for Ear and labyrinth disorders

Filter View AE/SOC

Expand all

1

March 20, 2025 Journal Suspected

On-Target Severity

Case report of a 87-year-old man with metastatic cutaneous squamous cell carcinoma who developed severe hypersensitivity reactions after receiving pembrolizumab (200 mg IV) and cemiplimab (350 mg IV). Other adverse events are listed.

Drugs (1) pembrolizumab Show structures

Adverse Event Ear swelling Alert Phase Postmarketing

2

February 13, 2025 Regulatory Agency Communication

Confirmed/Reported On-Target Causality

Adverse reactions reported in clinical trials with Hetronify with frequency not known included myositis, chronic obstructive pulmonary disease, respiratory failure, mouth ulceration and proctitis. Other adverse drug reactions are listed. [Data from EMA...

Drugs (1) serplulimab Show structures

Adverse Event Tinnitus Alert Phase Clinical Frequency Unknown

①出力したいSOCグループを選択
※AE,SMQ単位でも出力することが可能

②出力ボタンをクリック

レファレンスの一括出力

セーフティアラートごとにリンク先のレファレンス情報へ直接アクセス頂けます。

	A	B	C	D
1			Association based on reference	
2	2025-03-20	Journal	Suspected	Case report of a 87-year-old man with metastatic cutaneous squamous cell carcinoma who dev severe hypersensitivity reactions after receiving pembrolizumab (200 mg IV) and cemiplimab (200 mg IV). Other adverse events are listed.
3	2025-02-13	Regulatory Agency Communication	Confirmed/Reported	Adverse reactions reported in clinical trials with Hetronify with frequency not known included chronic obstructive pulmonary disease, respiratory failure, mouth ulceration and proctitis. Oth adverse drug reactions are listed. [Data from EMA European public assessment report for Hetronify (serplulimab; PD-1 inhibitor)]
4	2025-02-13	Regulatory Agency Communication	Confirmed/Reported	Uncommon (≥1/1,000 to <1/100) adverse drug reactions reported in clinical trials with Hetronify included septic shock, skin infection and enteritis infectious. [Data from EMA European public assessment report for Hetronify (serplulimab; PD-1 inhibitor)]
5	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
6	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
7	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
8	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
9	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
10	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]
11	2024-09-30	Regulatory Agency Communication	Confirmed/Reported	Common (≥1/100 to <1/10) adverse drug reactions reported in clinical trials with Loqtorzi inclu pneumonia, leukocytosis and hyperthyroidism. Other adverse drug reactions are listed. [Data from EMA European public assessment report for Loqtorzi (toripalimab-tpzi; PD-1 inhibitor)]

V	W	X	Y	Z	
Reference date	Reference Title	Citation	PubMed ID	Clinical trial ID	Link to OFF-X
2024-10-19	Severe hypersensitivity reactions to 2 immunotherapy agents in a patient with cutaneous squamous cell carcinoma	Am J Health Syst Pharm. 2024 Oct 19;:zxae286	39425965		https://www.ema.europa.eu/en/medicines/human/EPAR/hetronify/hetronify.htm
2025-02-11	Hetronify (serplulimab)	EMA European public assessment report, Hetronify (serplulimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/hetronify/hetronify.htm
2025-02-11	Hetronify (serplulimab)	EMA European public assessment report, Hetronify (serplulimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/hetronify/hetronify.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm
2024-09-24	Loqtorzi (toripalimab)	EMA European public assessment report, Loqtorzi (toripalimab)			https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi/loqtorzi.htm

活用事例1

ターゲット分子に関連する安全性情報を網羅的に収集

Target Record Snapshot

Targets

分子に関連したMOA,リガンド、バリエーションを選択し、該当する安全性情報を表示

情報更新時のアラート通知受信設定機能へのアクセス

Keep me posted

検索ボックスにて特定のTarget分子名を入力。[]内に記載された候補一覧から該当分子を選択

他のデータベース（外部またはクラリベイト製品）へのリンク

各ポートレットを選択展開することで、分子の作用カテゴリ別に関連医薬品、最新または警告関連の安全性情報、規制当局発表の安全性情報、対象となる治療領域を表示

Safety alerts – 個々の安全性報告の内容を確認

Targets

Target: Androgen receptor / Antagonists

Comparative table builder Keep me posted

Snapshot Safety alerts Target safety profile Comparative views Biological context

Adverse Events

▼ Blood and lymphatic system disorders DME

● Agranulocytosis DME

● Anaemia macrocytic

● Anaemia megaloblastic

● Anaemia

● Aplasia pure red cell DME

● Aplastic anaemia DME

● Blood disorder

● Bone marrow disorder

Showing 2 safety alerts for Agranulocytosis (Blood and lymphatic system disorders)

Filter View AE/SOC

^ Collapse all

January 17, 2025 • Journal Suspected

Pharmacovigilance study comparing the safety signals of adverse events associated with novel hormonal agents (abiraterone, apalutamide, enzalutamide and darolutamide) using data from the FAERS database. Safety issues are listed.

Drugs (1) apalutamide Show structures

Type On/off-target
Drug Alert Not Specified

Source information See all alerts

Reference date	Title	Citation
December 16, 2024	A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database	Expert Opin Drug Saf. 2024 Dec 16:1-10 PubMed 39668443

Adverse Event Agranulocytosis DME

Alert Phase Postmarketing

Severity

OFF-X Target/Class Score:

Safety alertsが作成されたAE一覧について表示形式（SOC/SMQ分類）を変更したり、フィルターによりAEの表示を限定することが可能

Safety alertsごとに関連医薬品の構造式やリファレンスへの外部リンク、当該リファレンスを基に作成されたその他のSafety alerts一覧へアクセス可能

Additional references – 安全性情報に関連したその他のレファレンスを検索

Additional referencesでは、安全性や毒性のキーワードと機械学習法を用いて同定された標的分子または対象薬剤を含む文献をリストアップして表示します。 ※これらの文献は編集員によるマニュアルキュレーションは実施されていません。

Target
Androgen receptor

Snapshot Safety alerts Target

Additional references

Showing 11

Search Target/Gene/Drug

Found in

Search safety keyword

Section

Download

Target/Gene/Drug	Found in	Safety Keyword	Section	Title	Citation	Reference date	PMID ↓
ar	Title/Abstract	rhinitis	Title/Abstract	Nutraceuticals and non-pharmacological remedies for managing patients with allergic rhinitis.	Minerva Pediatr (Torino) 2022 10 25;	2022-10-25	36282486
ar	Title/Abstract	allergic asthma	Title/Abstract	A real-world retrospective study of safety, efficacy, compliance and cost of combination treatment with rush immunotherapy plus one dose of pretreatment anti-IgE in Chinese children with respiratory allergies.	Front Immunol 2022 13; 1024319	2022-01-01	36268011
		allergic rhinitis	Title/Abstract				
		asthma	Title/Abstract				
		retrospective study	Title/Abstract				
		rhinitis	Title/Abstract				
		Reference's MeSH terms					
ar	Title/Abstract	allergic rhinitis	Title/Abstract	The Association between Allergic Rhinitis and COVID-19: A Systematic Review and Meta-Analysis.	Int J Clin Pract 2022 2022; 6510332	2022-01-01	36249911
		coronavirus disease 2019	Title/Abstract				
		rhinitis	Title/Abstract				

ターゲット分子、遺伝子、医薬品名および安全性・毒性のキーワードを選択したのちに言及箇所を指定し、レファレンスを検索可能。

フィルターが無効の場合、最も関連性の高い文献（キーワード近接性に基づく）のみ表示。フィルターを有効にすると、すべての文献（関連性の低いものを含む）が表示

Show all references (including less relevant ones)

Target safety profile

Master view – ターゲットに関連したSafety Alertsの総計を表示

Target Androgen receptor / Antagonists

Snapshot Safety alerts Target safety profile Comparative views Biological context

Master view

Showing 1,188 adverse events for Androgen receptor Antagonists

Filter 1 hidden Heat map

Adverse event • System Organ Class	OFF-X Target/Class Score	Classifier tags	Alert type				Alert phase				Tools		
			Number of alerts	Class alerts	Drug alerts		Preclinical	Clinical					
Anaemia • Blood and lymphatic system disorders	Very high	On-Target Causality Severity	97	12	4	0	93	12	0	0	97	12	⋮
Asthenia • General disorders and administration site conditi...	Very high	Causality Severity	90	12	5	0	85	12	0	0	90	12	⋮

Anaemia • Blood and lymphatic system disorders

Alerts Read across

Showing 97 alerts for Androgen receptor Antagonists and Anaemia

Expand all

- March 4, 2025 • Congress Alert Confirmed/Reported
Phase I study of enzalutamide (androgen receptor antagonist) with or without metformin (EZH2/PRC2 inhibitor) in 82 patients with metastatic castration-resistant prostate cancer. The most common treatment emergent adverse events (TEAEs) with enzalutamide/metformin were diarrhea (78% patients [n=41]), decreased appetite and dysgeusia (58.5% each). TEAEs with...
Drug (4): enzalutamide Show structures
- January 29, 2025 • Journal Confirmed/Reported
Phase III study of enzalutamide (androgen receptor antagonist) 160 mg qd alone or in combination with talazoparib (T, PARP-1/2 inhibitor; 0.5 mg qd) in patients with metastatic castration-resistant prostate cancer. The most common all causality treatment-emergent adverse events (TEAEs) included anemia (80%/39 patients with EZ; 17%/401 with T), neutropenia (38%...
Drug (4): enzalutamide Show structures
- December 12, 2024 • Journal Suspected
Systematic review evaluating the risk associated with denegest in patients with endometriosis. The most adverse reactions included abnormal uterine bleeding (55 [95% CI: 3.7-7.3]) and amenorrhea (3.7 [2.4-5.2]). Other safety issues are listed.
Drug (4): denegest Show structures

Anaemia • Blood and lymphatic system disorders

Alerts Read across

Showing 12 drugs in 97 alerts for Androgen receptor Antagonists and Anaemia

Show all structures

apalutamide Small molecule • Launched High 3 3 0 FDA	bicalutamide Small molecule • Launched High 3 1 0 FDA PMDA	cyproterone acetate Small molecule • Launched High 3 0 0 PMDA	darolutamide Small molecule • Launched High 3 5 0 PMDA
deutazulutamide Small molecule • Phase II Low 1 1 0	denegest Small molecule • Launched High 1 5 0 PMDA	enzalutamide Small molecule • Launched Very high 24 22 0 PMDA	flutamide Small molecule • Launched High 2 0 0 PMDA
masoprofen Small molecule • Discontinued Low 1 0 0	prolactinamide Small molecule • Launched Medium 7 2 0	revlutamide Small molecule • Phase II Low 1 1 0	sevitronel Small molecule • Phase II Low 0 1 0

MedDRA hierarchy classification (v27.1)

Non-MedDRA terms are included to expand coverage.

- SOB - Blood and lymphatic system disorders [DME] Very high On-Target Causality Severity 221
- HLGT - Anaemias nonhaemolytic and marrow depression [DME] Very high On-Target Causality Severity 106
- HLGT - Anaemia deficiencies Very low On-Target Causality Severity 1
- HLGT - Anaemia NEC Very high On-Target Causality Severity 102
- PT - Anaemia macrocytic Very low Causality 3
- PT - Anaemia megaloblastic Very low Causality 1
- PT - Anaemia Very high On-Target Causality Severity 97
- PT - Normochromic anaemia Very low Causality 1
- HLGT - Marrow depression and hypoplastic anaemias [DME] Very low Causality Severity 3
- HLGT - Coagulopathies and bleeding diatheses (excl thrombocytopenia) [DME] Very low Causality Severity 4
- HLGT - Haematological disorders NEC Very low Causality 14
- HLGT - Haemolyses and related conditions [DME] Very low Causality Severity 7
- HLGT - Platelet disorders [DME] High Causality Severity 28
- HLGT - Spleen, lymphatic and reticuloendothelial system disorders Very low On-Target Causality Severity 9
- HLGT - White blood cell disorders [DME] High Causality Severity 53
- SDC - Cardiac disorders [DME] Very high On-Target Causality Severity 345
- SDC - Congenital, familial and genetic disorders [DME] Low On-Target Causality Severity 34

Safety alerts数または関連Drug数を選択すると、選択したAE区分におけるAlert一覧および関連医薬品ごとのAEとの関連度、Alert数・構造式を表示

Toolコラムにて「・・・」を選択すると該当のAEについてMedDRAの階層を表示

Target safety profile

Translational safety – 前臨床・臨床・市販後までの有害事象を俯瞰し関連性を考察

Target Safety Explorer interface showing a table of adverse events and safety alerts. The interface includes a top navigation bar with 'Target', 'Androgen receptor / Antagonists', and a 'Comparative table builder' button. A 'Target safety profile' dropdown menu is open, showing 'Master view' and 'Translational safety' (highlighted). The main table lists adverse events like 'Infertility male', 'Reproductive toxicity', 'Azoospermia', 'Testicular atrophy', 'Weight abnormal', 'Seizure', and 'Sexual dysfunction'. Each row shows the event name, system organ class, OFF-X Target/Class Score, and a detailed table of safety alerts across various phases and species. A search bar is present on the left, and a 'Tools' column on the right allows for further actions. Annotations in Japanese explain the search and tool functions.


Annotations (Japanese):

- 特定のAEを検索して表示 (Search for specific adverse events and display)
- Toolsを選択すると、特定のAE区分におけるSafety Alert数を同じMOAをもつ医薬品ごとに内訳参照、特定のAEのTranslational safetyに移行、MedDRAの階層を表示 (When selecting Tools, you can view the breakdown of Safety Alert numbers for specific adverse event categories by MOA, navigate to the Translational safety for specific adverse events, and display the MedDRA hierarchy)
- カーソルを合わせ数値をクリックし、報告された動物種、個々のSafety alertsや関連医薬品の一覧へアクセス (Click the number with the cursor to access the list of reported animal species, individual safety alerts, and related drugs)
- Excel出力 (Excel output)

Target safety profile

Heat map – 特定のターゲットアクションに関するすべての有害事象をグループ化


Heatmapでは特定のターゲットアクションに関する全ての有害事象が、SOCまたはSMQごとにグループ化されて表示されます。



- 四角の色は「同じターゲットに作用する医薬品クラスー有害事象」の組み合わせについて蓄積されたセーフティアラートに基づき、当該「医薬品クラスー有害事象」の関連性を示すエビデンスの強さを計算した Target/Class Scoreから分類しております。
- 四角の大きさはアラートの数に比例します。

Comparative views

Comparative drug safety evidence – 特定のターゲットアクションをもつすべてのドラッグを比較表示



New

Comparative views

Comparative drug table builder – 関心のあるターゲットアクション（ドラッグ）の比較表を独自に作成

Targets

Targets

Type target, gene or UniProt ID and select

Add drugs acting on any selected target-actions

Add drugs sh

Selected target-actions

JAK1

Inhibitors

Androgen receptor

Antagonists

Modulators

Antagonists

Agonists

Degraders

Apply

Clear all

2 targets selected

Build table

Comparative table builder

Edit table

Filter

View

SOC

Heat map

Number of alerts

System Organ Class

Investigations

General disorders and administration site conditions DME

Reproductive system and breast disorders

Cardiac disorders DME

Injury, poisoning and procedural complications

Vascular disorders

Psychiatric disorders DME

Hepatobiliary disorders DME

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Endocrine disorders

25

Androgen re...
Modulators

1159

824

630

479

471

467

403

307

215

132

9,610

Comparative table builder

Edit table

Filter

View

SOC

Heat map

Number of alerts

System Organ Class

General disorders and administration site conditions DME

Investigations

Injury, poisoning and procedural complications

Reproductive system and breast disorders

Vascular disorders

Cardiac disorders DME

Metabolism and nutrition disorders

Psychiatric disorders DME

Blood and lymphatic system disorders DME

Nervous svstem disorders DME

26

Androgen re...
Antagonists

691

659

419

408

376

345

319

244

221

712

7,170

JAK1
Inhibitors

923

2388

621

152

730

539

383

91

1460

882

17,849

検索しているターゲットがデフォルトで組み込まれます

JAK1が新たに表に追加

関心のあるターゲットを追加

MOA、バリエントを選択

New

Biological context

Pathway Maps– 病理学的・生理学的パスウェイを視覚的に表示

関心のあるターゲットを軸にした周辺のターゲットとの比較表の作成

Targets

Target
Androgen receptor

Snapshot Safety alerts Target safety profile Comparative views Biological context

Pathway maps

All Pathological Physiological

AKT(PKB) signaling in Prostate Cancer

Androgen receptor activation and downstream signaling in Prostate cancer

Androgen signaling in hepatocellular carcinoma (HCC)

Breast cancer (general schema)

COVID-19: SARS-CoV-2 entry into target cells

Cell cycle progression in Prostate Cancer

Development_Androgen receptor in non-reproductive systems development

Development_Androgen receptor in reproductive system development

EGFR signaling in Prostate Cancer

FGF signaling in Prostate Cancer

G-protein signaling_Rac3 regulation pathway

Pathway maps

Androgen receptor activation and downstream signaling in Prostate cancer

Default Safety alerts Description Legend

Pathway maps

Androgen receptor activation and downstream signaling in Prostate cancer

Default Safety alerts Filter Actions

Comparative table builder

Please select the targets you want to compare

☒ All targets in the highlighted cascade

☐ Direct interactions (shown in the interactions table)

Cancel Continue

Androgen receptor

Transcription factor

Highest Phase: Launched

19154 Safety Alerts 3833 Serious/severe safety alerts

Showing 59 interactions

From	Mechanism	To
STAT3	+ Binding	Androgen receptor
ERK2	+ Phosphorylation	Androgen receptor
Rb protein	+ Binding	Androgen receptor
NCOA1 (SRC1)	+ Binding	Androgen receptor
ESR2 (nuclear)	+ Binding	Androgen receptor

Pathway maps

Androgen receptor activation and downstream signaling in Prostate cancer

Default Safety alerts Filter Actions

Build comparative table

Build comparative table

Download

Pathway Mapsや各アイコン等の説明

ターゲット情報に加え、相互作用情報もリスト

パスウェイに存在する全てのターゲットの比較表を作成

パスウェイマップを出力

ターゲットに紐づく Safety Alertの数を表示


ターゲットに紐づく Safety Alertを特定のAEやActionによって絞り込み

活用事例2

特定の医薬品に関わる安全性報告を確認

医薬品の安全性報告を確認する

Drugs and biologics



検索ボックスにて特定の医薬品名を入力
[]内に記載された候補一覧から該当医薬品を選択

情報更新時のアラート通知
受信設定機能へのアクセス

Drug **nivolumab**

Comparative table builder Keep me posted

Snapshot Safety alerts Drug safety profile Comparative views

Drug type	Highest phase	OFF-X drug ID
Biologic	Launched 2014	140816
Product category/modality	Drug names (10)	Organizations (8)
Cancer Immunotherapy	Nivolumab BMS	Amgen Inc.
	Opdivo	Biocad CJSC
	Xdivane	Bristol-Myers Squibb Co.
	ABP-206	Luye Pharma Group Ltd.
	BCD-263	National Cancer Institute (NCI)
	BMS-936558	
	JPB-898	
	...	

Other databases (external or Clarivate products) links

- Cortellis Drug Discovery Intelligence (6)
1243105, 1298403, 1049604, 421460, 1132935, 1300010
- Cortellis Competitive Intelligence (2)
108155, 54804
- DrugCentral (1)
nivolumab
- ChEMBL (1)
CHEMBL2108738

各ポートレットを選択展開することで、
医薬品の区分、最新または警告関連の安全
性情報、規制当局発表の安全性情報、
対象となる治療領域を表示

他のデータベース（外部または
クラリベイト製品）へのリンク

Pharmacology profile

Latest and pinned alerts

Regulatory relevance

Therapeutic applications

AEごとのFDA Approval packageにおける記載を確認する

Drug
nivolumab

Comparative table builder

Keep me posted

Snapshot

Safety alerts

Drug safety profile

Con

Master view

Showing 2,688 adverse events for

Filter

1 hidden

Adverse event • System Organ

Heat map

Mounting evidence chart

Death • General disorders and ac

Diarrhoea • Gastrointestinal disorders

Hypothyroidism • Endocrine disorders

Immune-mediated adverse reaction • Immune system disor...

Pneumonitis • Respiratory, thoracic and mediastinal disorders

Pruritus • Skin and subcutaneous tissue disorders

Rash • Skin and subcutaneous tissue disorders

Abdominal discomfort • Gastrointestinal disorders

Alert phase

Preclinical

Clinical

Text mining FDA SBA

FDA

EMA

PMDA

Tools

	Drug alerts	Combination alerts	Preclinical	Clinical	Text mining FDA SBA	FDA	EMA	PMDA	Tools						
Death • General disorders and ac	1	226	1	290	82	3	1	556	83	0					
Diarrhoea • Gastrointestinal disorders	1	317	1	606	213	2	1	957	214	4					
Hypothyroidism • Endocrine disorders	1	255	1	328	112	1	0	615	113	2					
Immune-mediated adverse reaction • Immune system disor...	1	627	1	451	90	14	1	1238	91	1					
Pneumonitis • Respiratory, thoracic and mediastinal disorders	1	290	1	268	93	5	1	619	94	5					
Pruritus • Skin and subcutaneous tissue disorders	1	219	1	394	136	0	0	647	137	3					
Rash • Skin and subcutaneous tissue disorders	1	260	1	412	144	1	0	711	145	3					
Abdominal discomfort • Gastrointestinal disorders	0	8	1	20	14	0	0	28	15	0					

Drug Safety Profileタブをクリックし、Master Viewを選択

Text Mining FDA SBAの列にて、AEごとのカウント数をクリック

AEごとのFDA Approval packageにおける記載を確認する

OFF-X text mining FDA Summary Basis of Approval (SBA)

The following table lists FDA Summary Basis of Approval (SBA) documents where particular adverse event terms have been found by our proprietary text mining tools. The original document with the adverse event terms highlighted is accessible via the Source link.

Adverse Event	Document type	Term	Number of occurrences	Source
Diarrhoea	Clinical Pharmacology Biopharmaceutics Review	diarrhea	1	Source
		diarrhoea	3	Source
	Medical Review	diarrhea	28	Source
	Pharmacology Review	diarrhea	4	Source
	Summary Review	diarrhea	2	Source

Sourceをクリックすると、ドキュメントタイプごとに記載箇所を確認可能

どのAEが、どのDocumentに、どの用語で、どのくらいの記載数があるかを表示

AE、Document typeの表示の切り替え

AE軸、Document type軸で表示の切り替え

関連用語の切り替え

Documentの出力

記載箇所を黄色ハイライト

Real-world evidence analysis

Main view—当局集計（JADER・FAERS）の安全性報告一覧を確認する

Drug nivolumab

Snapshot Safety alerts **Drug safety profile** Comparative

Real-world evidence analysis

Showing 6,124 adverse events for 27 System Organ Classes

Filter 4 hidden columns View AE/SOC

Master view
Translational safety
Real-world evidence analysis
Heat map
Mounting evidence chart

① Drug safety profileを選択し、Real-world evidence analysisをクリックする

Main view Comparative report analysis Concomitant drug analysis Report details and analysis

表示するAEのフィルタリング
表示形式区分の変更（AE/SOC）
表示するコラムの選択

安全性報告数、報告割合、第1報からの経過年数

特定のAEを検索して表示

当局発表のLabel情報に基づく Safety alertへアクセス

Adverse event • System Organ Class	OFF-X Drug Score	FDA	EMA	PMDA	Number of reports	% of reports	First reported	Evans	X-squared	PRR025	ROR025	GPS (EB05)	IC025	Tools
Malignant neoplasm progression • Neoplasms benign, mali...	Very high				10,711	4.5	>5 years							
Off label use • Injury, poisoning and procedural complications					9,012	3.8	>5 years							
Diarrhoea • Gastrointestinal disorders	Very high				4,812	2	>5 years							
Fatigue • General disorders and administration site conditions	High				4,385	1.8	>5 years							
Intentional product use issue • Injury, poisoning and proce...					3,575	1.5	>5 years							
					3,291	1.4	>5 years							

該当のAEについてMedDRAの階層を表示

Real-world evidence analysis

Comparative report analysis—同じ作用機序の薬剤間で安全性報告数を一覧比較する

Drug
nivolumab

Snapshot Safety alerts Drug safety profile Comparative

Real-world evidence analysis

Comparing 13 drugs (launched, sharing primary target action)

Filter

View
AE/SOC

Database
FAERS

Edit drugs

Drugs sharing primary target action: PD-1 Inhibitors

Launched
cadonilimab camrelizumab cemiplimab dostarlimab pembrolizumab
pocotenimab retifanlimab serplumab sintilimab tislelizumab
toripalimab zimberelimab

In development

Any other drugs

Reset Cancel Apply

Comparative table builder

Keep me posted

Main view **Comparative report analysis** Concomitant drug analysis Report details and analysis

一覧比較する医薬品を指定する

Adverse event • System Organ Class	nivolumab Launched 2014			pembrolizumab Launched 2014			cemiplimab Launched 2018			camrelizumab Launched 2019			Tools
	OFF-X Drug Score	Number of reports	% of reports	OFF-X Drug Score	Number of reports	% of reports	OFF-X Drug Score	Number of reports	% of reports	OFF-X Drug Score	Number of reports		
Death • General disorders and administration site conditions		10,711	4.5		4,452	1.9		118	2		17		
Malignant neoplasm progression • Neoplasms benign, mali...		9,012	3.8		8,857	3.9		16	0.3		8		
Off label use • Injury, poisoning and procedural complications		4,812	2		3,423	1.5		92	1.5		61		
Diarrhoea • Gastrointestinal disorders		4,385	1.8		4,109	1.8		47	0.8		46		
Fatigue • General disorders and administration site conditions		3,575	1.5		3,845	1.7		100	1.7		48		
Intentional product use issue • Injury, poisoning and proce...		3,291	1.4		81			2			1		
Pyrexia • General disorders and administration site conditions		3,250	1.4		2,823	1.2		91	1.5		33		
Nausea • Gastrointestinal disorders		2,655	1.1		2,654	1.2		50	0.8		48		

New

Real-world evidence analysis

Concomitant drug analysisー単剤時と併用時の安全性報告数を確認する

Drugs and biologics

Drug
nivolumab

Comparative table builder

Keep me posted

Snapshot

Safety alerts

Drug safety profile

Comparative views

Real-world evidence analysis

Main view

Comparative report analysis

Concomitant drug analysis

Report details and analysis

Adverse event

Death

SMQ

Broad SMQ terms

Case ID

Filter

Database

FAERS

Drug • Highest phase	Death	Concomitant reports	Reports
nivolumab • Biologic • Launched 2014	OFF-X Drug Score FDA EMA PMDA		10,711
ipilimumab • Biologic • Launched 2011	FDA EMA PMDA	2,666	3,553
ondansetron • Small molecule • Launched 1990		407	8,801
oxycodone • Small molecule • Launched 1917	FDA	279	29,128
acetaminophen • Small molecule • Launched 1955	FDA	241	14,161
levothyroxine • Small molecule • Launched 1955		230	11,597

関心のあるAEを入力

FAERS,JADERの選択


併用時の安全性報告数

単剤時の安全性報告数

Real-world evidence analysis


Report details and analysis—安全性報告の蓄積推移を一覧比較する

Drugs and biologics



Mounting evidence chart

特定のAEについてOFF-X Drug Scoreに基づくエビデンスレベルの推移を表示



Combination（合剤/併用）の安全性報告を確認する

※併用の検索例

Targets Drugs and biologics **Drug combinations** Adverse events

Search: nivolumab/ipilimumab

Results:

- ipilimumab/nivolumab
- ipilimumab/nivolumab/radiotherapy
- BMS-986156/ipilimumab/nivolumab
- BMS-986156/ipilimumab/nivolumab/radiotherapy
- BMS-986178/ipilimumab/nivolumab

Selected result: Drug combination ipilimumab/nivolumab

Snapshot Safety alerts Combination safety profile

OFF-X combination ID: 86

Components:

- ipilimumab (Launched 2011, Y Biologic, Primary target action: CTLA-4 Inhibitors)
- nivolumab (Launched 2014, Y Biologic, Primary target action: PD-1 Inhibitors)

Latest and pinned alerts

Regulatory relevance

Therapeutic applications

※合剤の検索例

Targets Drugs and biologics **Drug combinations** Adverse events

Search: alogliptin/met

Results:

- alogliptin/metformin

Selected result: Drug combination alogliptin/metformin

Snapshot Safety alerts Combination safety profile

Product category/modality (2): Biguanides, Antidiabetic Drugs
Fixed-Dose Combinations

Highest phase: Launched 2013

Combination names (3): Inisync, Kazano, Vipdomet

OFF-X combination ID: 1812

Corollis Drug Discovery Intelligence (1): 669872

Organizations (2): Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd.

Components:

- alogliptin (Launched 2010, Primary target action: DPP4 Inhibitors)
- metformin (Launched 1959, Primary target action: AMPK Activators)

Latest and pinned alerts

Regulatory relevance

Therapeutic applications

New

Combination（合剤/併用）の安全性報告を確認する

Drug combinations

Drug combination
ipilimumab/nivolumab

Snapshot **Safety alerts** Combination safety profile ▾

Adverse Events ▾ →

- ▼ Blood and lymphatic system disorders DME
 - Agranulocytosis DME
 - Anaemia
 - Antiphospholipid syndrome
 - Aplasia pure red cell DME
 - Aplastic anaemia DME
 - Autoimmune haemolytic anaemia DME
 - Autoimmune neutropenia
 - Autoimmune pancytopenia
 - Blood disorder
 - Bone marrow failure DME

Showing 1 safety alert for **Agranulocytosis** (Blood and lymphatic system disorders)

Filter View

1

May 10, 2020 • Journal Confirmed/Reported

Analysis of the FDA Adverse Event Reporting System database for hematological toxicities with immune checkpoint inhibitors. Adverse events with ROR025 >1 (including fatal cases) of nivolumab, pembrolizumab, cemiplimab, ipilimumab, atezolizumab, avelumab, durvalumab, ipilimumab + pembrolizumab, ipilimumab + nivolumab, and ipilimumab + pembrolizumab + nivolumab are listed.

Combinations (1) ipilimumab/nivolumab

Type
Drug Alert

Source information See all alerts

Reference date	Title	Citation
May 8, 2020	Hematological Toxicities in Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019	Hematol Oncol. 2020 May 8
		PubMed 32383782

Filter

Monotherapy alerts

Adverse event filters

- Adverse event | System Organ Class | SMQ
- OFF-X Combination Score

Safety alert filters

- Classifier tags
- Clinical trial ID | Patient condition | Patient population
- Alert phase | Species
- Source type
- Association based on reference
- Time period

Monotherapy alerts

Safety alerts associated with monotherapies of the drug combination are hidden by default.

☒ Show monotherapy alerts of the drug combination (20,237)

スライダーをONにすることで単剤のSafety Alertを追加表示

Clear all filters Cancel Apply

併用時のSafety Alertを表示

New

Combination safety profile

MASTER VIEW – Combinationに関連したSafety Alertsの総計を表示

Drug combinations

Drug combination
ipilimumab/nivolumab

Keep me posted

SnapshotSafety alertsCombination safety profile

Master view

Showing 2,305 adverse events

Translational safety

Heat map

Adverse event • System Organ Class


Monotherapy alerts

	OFF-X Combination Score	Classifier tags	Frequency in clinical trials	Number of alerts	Combination alerts	ipilimumab	nivolumab
Abdominal pain • Gastrointestinal disorders	Very high	CausalitySeverity	1 - 54.76%	125	3	43	25
Acute kidney injury • DME • Renal and urinary disorders	Very high	CausalitySeverityPharmacogenomics	≥0.1 - 11.9%	153	3	57	19
Alanine aminotransferase increased • Investigations	Very high	CausalitySeverity	1 - 33.33%	297	3	104	44
Anaemia • Blood and lymphatic system disorders	Very high	CausalitySeverityPharmacogenomics	1 - 85.7%	209	3	68	26
Aspartate aminotransferase increased • Investigations	Very high	CausalitySeverity	1 - 38.1%	288	3	103	41
Asthenia • General disorders and administration site conditions	Very high	CausalitySeverity	≥1 - 22.2%	167	3	44	20
Diarrhoea • Gastrointestinal disorders	Very high	CausalitySeverityPharmacogenomics	<1 - 50%	638	3	189	120
Fatigue • General disorders and administration site conditions	Very high	CausalitySeverityPharmacogenomics	≥5 - 85.71%	506	3	157	58
Hyperthyroidism • Endocrine disorders	Very high	CausalitySeverity	≥0.1 - 16.67%	251	3	86	38
Hypothyroidism • Endocrine disorders	Very high	CausalitySeverityPharmacogenomics	>1 - 33.33%	451	3	126	61

Combination safety profile

Heat map – 特定のCombinationに関するすべての有害事象をグループ化

Heatmapでは特定のターゲットアクションに関する全ての有害事象が、SOCまたはSMQごとにグループ化されて表示されます。



- 四角の色は、Drug ScoreやTarget/Class Scoreと同様のルールに基づいたアルゴリズムで算出され、OFF-XにあるすべてのSafety Alertに基づく、特定の「コンビネーション有害事象」の関連性を示すエビデンスの強さを計算したCombination Scoreから分類しております。
- 四角の大きさはアラートの数に比例します。

活用事例3

特定の有害事象に関連する作用機序を網羅的に評価

特定の有害事象について原因となる作用機序を網羅的に評価

Adverse events

The screenshot displays the 'Adverse events' tab in a software interface. A search bar at the top contains the text 'asthenia'. Below the search bar, there is a toggle switch for 'Synonyms' and a label 'MedDRA terminology (27.1)'. A list of search results is shown, including 'Asthenia [Asthenia] (General disorders and administration site conditions)', 'Immune-mediated myasthenia gravis [Immune-mediated myasthenia gravis] (Nervous system disorders)', 'Myasthenia gravis [Myasthenia gravis] (Nervous system disorders)', and 'Myasthenia gravis crisis [Myasthenia gravis crisis] (Nervous system disorders)'. A green callout box points to the first result with the text: '検索ボックスにて特定のAE名を入力 []内に記載された候補一覧から該当AEを選択'.

Targets Drugs and biologics Drug combinations Adverse events

Search: asthenia

Synonyms

MedDRA terminology (27.1)

Asthenia [Asthenia] (General disorders and administration site conditions)

Immune-mediated myasthenia gravis [Immune-mediated myasthenia gravis] (Nervous system disorders)

Myasthenia gravis [Myasthenia gravis] (Nervous system disorders)

Myasthenia gravis crisis [Myasthenia gravis crisis] (Nervous system disorders)

検索ボックスにて特定のAE名を入力 []内に記載された候補一覧から該当AEを選択

特定の有害事象について原因となる作用機序を網羅的に評価

Master view – 作用機序ごとにSafety Alert一覧を表示

Adverse events

Adverse event
Asthenia

Comparative table builder

Targets

Drugs and biologics

Master view

Showing 1,106 target-actions

Filter

1 hidden column

• フィルターによるAEの限定

• 表示するコラムの選択

Target • Action			Alert type					
	OFF-X Target/Class Score ↓	Classifier tags	Number of alerts		Class alerts		Drug alerts	
alpha1-Adrenoceptor • Antagonists		On-Target Causality	47	11	6	4	41	1
Androgen receptor • Antagonists	Very high	Causality Severity	90	12	5	0	85	1
beta-Adrenoceptor • Antagonists	Very high	Causality	56	19	6	3	50	1
DNA gyrase • Inhibitors	Very high	Causality Severity	35	14	10	6	25	1
DNA topoisomerase 4 • Inhibitors	Very high	Causality Severity	35	14	10	6	25	1
Hedgehog protein signaling • Inhibitors	Very high	Causality Severity	31	4	2	2	29	
MAO • Inhibitors	Very high	On-Target Causality	14	7	3	0	11	

特定のAEを検索して表示

?

特定の有害事象について原因となる作用機序を網羅的に評価

Adverse events

Translational safety – 開発ステージ別のSafety alert数を作用機序ごとに一覧表示

Adverse event

Asthenia

Comparative table builder

Targets

Drugs and biologics

Translational safety

Showing 1,085 target-actions

Filter

2 hidden columns

• フィルターによるAEの限定

• 表示するコラムの選択

Target • Action	OFF-X Target/Class Score	Biological Role & Preclinical Pharmacological Evidence					Clinical Pharmacological Evidence						
		Target Expression	Human Genetic variants	KO/KD Animal data	In vitro data / Patient samples	Preclinical	Phase I	Phase II	Phase III	Clinical Regulatory	Postmarketing	Phase not specified	
DNA topoisomerase 2 • Inhibitors	Medium					4 2 Species 2	8 8	13 6	6 3	11 7	3 3	4	
FAAH • Inhibitors						3 1 Species 3	2 2						
JAK • Inhibitors	Low					2 2 Species 1	5 4	7 5	25 5	7 4	7 4	4	
beta-Adrenoceptor • Antagonists	Very high					2 2 Species 2	1 1	2 2		38 18	9 7	4	
beta1-Adrenoceptor • Antagonists	High					2 2 Species 2	1 1			21 13	5 4	2	
MAO • Inhibitors	Very high					2	2 2		1 1	6 4	1 1	2	
MAO-A • Inhibitors	Very high					2	1 1			2 2		1	
Tyrosine kinase • Inhibitors	High					1 1 Species 1	50 34	118 43	91 22	79 25	102 19	43	
PD-1 • Inhibitors	High					1 1 Species 1	80 23	118 18	64 7	16 7	56 8	26	

特定のAEを検索して表示



サポートのご案内

ユーザーサポートのご案内



カスタマーケア

☎ 0800-919-1307(フリーダイヤル)
(土日祝日を除く) 9:30~17:30
✉ ts.support.jp@clarivate.com

使い方やアクセス、データベースの収録内容に関するご質問はこちらまで。

専門スタッフが対応。使い方、アクセスなどにお困りの際は、気軽に日本語でお問い合わせが可能。




日本語製品サポートサイトへは以下のリンクからアクセスください。

<https://clarivate.com/life-sciences-healthcare/ja/training-support/cortellis/off-x/>


ユーザーサポートのご案内

ナレッジベースでは、各種操作説明資料、ウェブセミナーの録画、コンテンツ情報の詳細解説記事等にアクセス頂けます。



The screenshot shows a user support page with two main sections for congress alerts. The first section, titled "June 13, 2024 • Congress Alert", describes a real-world study of pegcetacoplan in patients with atrophy and lists adverse events. The second section, titled "June 11, 2024 • Congress Alert", describes real-world experience evaluating pegcetacoplan in patients with geographic atrophy. Below these are two more sections for regulatory agency communications. A "Resources & updates" dropdown menu is open, showing links to Product updates, Knowledge Base, Guided tours, Training resources, Online help & contact us, and Feedback & suggestions. The footer contains copyright information and links to the Legal center, Privacy notice, Cookie policy, and Manage cookie preferences. The "Knowledge base" link is highlighted with a blue box.

画面最下部までスクロールダウンし、
Knowledge Baseをクリックすることでも
アクセス頂けます。



The screenshot shows the Knowledge Base search page. At the top, there is a search bar with the placeholder text "Type your topic here..." and a "Search" button. Below the search bar, there is a section titled "What can we help you with?" which lists featured articles. The articles include "OFF-X Drug Score", "OFF-X Target/Class Score", "Drug record", "Target record", "Adverse event record", and "Safety alerts field description". Each article has a brief description of its content. On the left side of the page, there is a "What's new / Product updates" section. On the right side, there is a "General" section with a head icon.



Think forward

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.